Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial - Herrlinger, U; Tzaridis, T; Mack, F; Neurooncology Working Group of the German Cancer Society (Lancet, 2019)